Enhancing treatment success in inflammatory bowel disease: Optimising the use of anti-TNF agents and utilising their biosimilars in clinical practice
Author:
Funder
Samsung Bioepis and Biogen
Publisher
Elsevier BV
Subject
Gastroenterology,Hepatology
Reference54 articles.
1. The global burden of IBD: from 2015 to 2025;Kaplan;Nat Rev Gastroenterol Hepatol,2015
2. Risks and benefits of biologic therapy for inflammatory bowel diseases;D'Haens;Gut,2007
3. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review;Gisbert;Am J Gastroenterol,2009
4. Loss of response and need for adalimumab dose intensification in Crohn's disease: a systematic review;Billioud;Am J Gastroenterol,2011
5. ACG Clinical Guideline: ulcerative colitis in adults;Rubin;Am J Gastroenterol,2019
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Timing of proper introduction, optimization and maintenance of anti-TNF therapy in IBD: Results from a Delphi consensus;Digestive and Liver Disease;2024-01
2. Management of Non-response and Loss of Response to Anti-tumor Necrosis Factor Therapy in Inflammatory Bowel Disease;Frontiers in Medicine;2022-06-15
3. Immunology of Inflammatory Bowel Disease: Molecular Mechanisms and Therapeutics;Journal of Inflammation Research;2022-03
4. Biosimilar Uptake: The Importance of Healthcare Provider Education;Pharmaceutical Medicine;2021-07
5. Informing Patients about Biosimilar Medicines: The Role of European Patient Associations;Pharmaceuticals;2021-02-04
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3